Immune checkpoint blockade (ICB) generates anti-tumor response through the inhibition of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and/or programmed cell death protein 1 ligand (PD-L1). The gene discussed is CTLA4; the disease is neoplasm.